StockNews.com Downgrades Amgen (NASDAQ:AMGN) to Buy
StockNews.com Downgrades Amgen (NASDAQ:AMGN) to Buy
Amgen (NASDAQ:AMGN – Get Rating) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating in a research note issued on Thursday.
在週四發佈的一份研究報告中,斯托克新聞網的分析師將安進(納斯達克代碼:AMGN-GET)的評級從“強力買入”下調至“買入”。
Several other research analysts have also weighed in on AMGN. Barclays boosted their price objective on shares of Amgen from $234.00 to $240.00 and gave the stock an "underweight" rating in a research note on Wednesday, January 18th. Credit Suisse Group initiated coverage on shares of Amgen in a research note on Thursday, November 17th. They set an "underperform" rating and a $240.00 price objective on the stock. Royal Bank of Canada lifted their target price on shares of Amgen from $235.00 to $240.00 and gave the stock a "sector perform" rating in a report on Friday, November 4th. SVB Leerink lifted their target price on shares of Amgen from $256.00 to $282.00 and gave the stock a "market perform" rating in a report on Thursday, December 22nd. Finally, Wells Fargo & Company lifted their target price on shares of Amgen from $250.00 to $285.00 and gave the stock an "equal weight" rating in a report on Tuesday, January 3rd. Four analysts have rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $253.57.
其他幾位研究分析師也對AMGN發表了看法。巴克萊將安進股票的目標價從234.00美元上調至240.00美元,並在1月18日星期三的一份研究報告中將該股的評級定為“減持”。瑞士信貸集團在11月17日星期四的一份研究報告中啟動了對安進股票的報道。他們為該股設定了“表現不佳”的評級和240.00美元的目標價。加拿大皇家銀行在11月4日週五的一份報告中將安進股票的目標價從235.00美元上調至240.00美元,並給予該股“行業表現”評級。SVB Leerink將安進股票的目標價從256.00美元上調至282.00美元,並在12月22日週四的一份報告中給出了該股的“市場表現”評級。最後,富國銀行將安進股票的目標價從250.00美元上調至285.00美元,並在1月3日(星期二)的一份報告中給予該股“同等權重”的評級。四位分析師對該股的評級為賣出,四位分析師給出了持有評級,五位分析師給出了該公司股票的買入評級。根據MarketBeat的數據,該股的共識評級為持有,共識目標價為253.57美元。
Amgen Stock Down 0.5 %
安進股價下跌0.5%
Amgen stock opened at $253.65 on Thursday. The firm has a market capitalization of $135.34 billion, a PE ratio of 20.33, a P/E/G ratio of 1.82 and a beta of 0.67. The company's 50-day moving average is $272.02 and its 200-day moving average is $257.02. Amgen has a fifty-two week low of $214.39 and a fifty-two week high of $296.67. The company has a debt-to-equity ratio of 10.17, a current ratio of 1.68 and a quick ratio of 1.35.
週四,安進的股票開盤報253.65美元。該公司市值為1,353.4億美元,市盈率為20.33,市盈率為1.82,貝塔係數為0.67。該公司的50日移動均線切入位在272.02美元,200日移動均線切入位在257.02美元。安進的股價為214.39美元,為52周低點,52周高點為296.67美元。該公司的債務權益比為10.17,流動比率為1.68,速動比率為1.35。
Insider Buying and Selling at Amgen
安進的內幕買賣
In other Amgen news, SVP Nancy A. Grygiel sold 545 shares of the business's stock in a transaction dated Tuesday, November 8th. The shares were sold at an average price of $293.54, for a total value of $159,979.30. Following the completion of the sale, the senior vice president now owns 13,009 shares of the company's stock, valued at approximately $3,818,661.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.46% of the company's stock.
在安進的其他新聞中,高級副總裁南希·A·格里吉爾在11月8日星期二的交易中出售了545股安進股票。這些股票的平均價格為293.54美元,總價值為159,979.30美元。出售完成後,高級副總裁現在擁有該公司13,009股股票,價值約3,818,661.86美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的,該文件可通過美國證券交易委員會網站。內部人士持有該公司0.46%的股份。
Hedge Funds Weigh In On Amgen
對衝基金對安進持股
Hedge funds and other institutional investors have recently made changes to their positions in the company. EdgeRock Capital LLC acquired a new position in shares of Amgen in the 3rd quarter valued at approximately $25,000. Leelyn Smith LLC raised its position in shares of Amgen by 80.3% in the 3rd quarter. Leelyn Smith LLC now owns 110 shares of the medical research company's stock valued at $25,000 after buying an additional 49 shares in the last quarter. Capital Wealth Alliance LLC acquired a new position in Amgen during the 2nd quarter worth approximately $26,000. Glassy Mountain Advisors Inc. acquired a new position in Amgen during the 4th quarter worth approximately $26,000. Finally, Coston McIsaac & Partners acquired a new position in Amgen during the 2nd quarter worth approximately $27,000. 75.53% of the stock is currently owned by institutional investors and hedge funds.
對衝基金和其他機構投資者最近對他們在該公司的頭寸進行了調整。EdgeRock Capital LLC在第三季度收購了價值約2.5萬美元的安進股票的新頭寸。Leelyn Smith LLC在第三季度將其在安進股票的持倉提高了80.3%。Leelyn Smith LLC現在擁有110股這家醫療研究公司的股票,價值25,000美元,上個季度又購買了49股。資本財富聯盟有限責任公司在第二季度收購了安進的一個新頭寸,價值約2.6萬美元。Glassy Mountain Advisors Inc.在第四季度收購了安進的一個新頭寸,價值約2.6萬美元。最後,Coston McIsaac&Partners在第二季度在安進獲得了一個價值約2.7萬美元的新職位。75.53%的股票目前由機構投資者和對衝基金持有。
About Amgen
關於安進
(Get Rating)
(獲取評級)
Amgen, Inc is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA.
安進公司是一家生物技術公司,從事人類療法的發現、開發、製造和營銷。其產品包括以下品牌:Aranesp、Aimovig、Kanjinti、EVENITY、AMGEVITA、AVSOLA、BLINCETO、MVASI、Corlanor、Enbrel、Epogen、Imlyic、Kyprolis、Neulasta、NEUPOGEN、NPLATE、Parsabiv、Prolia、Repatha、Sensiar、Vectibix、Otezla、RIABNI和XGEVA。
Recommended Stories
推薦故事
- Get a free copy of the StockNews.com research report on Amgen (AMGN)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
- 免費獲取StockNews.com關於安進的研究報告(AMGN)
- 市場回顧周-1/23-1/27
- 為什麼Lucid在一天內飆升了近100%
- 利用這些鐵路股票實現增長和收入
- ASML預計今年芯片需求回升,提振銷售觀點
- KLA公司:在動盪不安的半市場中站穩腳跟
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.
接受安進日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對安進和相關公司的最新新聞和分析師評級的每日簡明摘要。